Lilly/Avid Alzheimer's Diagnostic May Need To Broaden Target Population Before Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
While florbetapir F 18 injection showed good results in terminal patients, Avid Radiopharmaceuticals will have to convince an FDA advisory panel that it can be used to diagnose patients in the early stages of Alzheimer's disease or other dementias.
You may also be interested in...
Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain
It appears the training program for Amyvid may still need some work, but Eli Lilly & Co. remains confident the diagnostic will gain FDA approval.
Can Amyvid Be An Important Alzheimer's Product Without An Alzheimer's Indication?
Members of the FDA advisory committee that reviewed Avid Radiopharmaceuticals' Amyvid appear less enthusiastic about the product's immediate prospects than the firm itself, but actually could be more enthusiastic about the diagnostic's long-term utility than even the sponsor.
Amyvid Approval Delay Seems Likely; Questions On Utility Of Training, Plaque Detection Itself Remain
It appears the training program for Amyvid may still need some work, but Eli Lilly & Co. remains confident the diagnostic will gain FDA approval.